# Psilocybin-facilitated Treatment for Cocaine Use

> **NCT02037126** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 40 (actual)

## Conditions studied

- Cocaine-Related Disorders

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT02037126
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02037126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02037126, "Psilocybin-facilitated Treatment for Cocaine Use". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02037126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*